Related content

Ii-Key/HER-2/neu MHC class-II antigenic epitope vaccine peptide for breast cancer

By Gillogly Michael   Kallinteris Nikoletta   Xu Minzhen   Gulfo Joseph   Humphreys Robert   Murray James  

Cancer Immunology, Immunotherapy, Vol. 53, Iss. 6, 2004-06 ,pp. : 490-496

Springer Publishing Company

Access to resources Recommend Favorite

Her-2/neu as Predictive Marker for Endocrine Therapy and Chemotherapy in Patients with Metastatic Breast Cancer

By Köstler Wolfgang J.   Zielinski Christoph C.  

Breast Cancer Research and Treatment, Vol. 81, Iss. 1, 2003-01 ,pp. : 73-84

Springer Publishing Company

Access to resources Recommend Favorite

Her-2/neu altered peptide ligand–induced CTL responses: implications for peptides with increased HLA affinity and T-cell-receptor interaction

By Dionne Sara   Myers Cheryl   Smith Margaret   Lake Douglas  

Cancer Immunology, Immunotherapy, Vol. 53, Iss. 4, 2004-04 ,pp. : 307-314

Springer Publishing Company

Access to resources Recommend Favorite

HER-2/Neu overexpression does not predict response to neoadjuvant chemotherapy or prognosticate survival in patients with locally advanced breast cancer

By Tulbah Asma   Ibrahim Ezzeldin   Ezzat Adnan   Ajarim Dahish   Rahal Mohammed   Weshi Amr   Sorbris Ralph  

Medical Oncology, Vol. 19, Iss. 1, 2002-03 ,pp. : 15-23

Humana Press, Inc

Access to resources Recommend Favorite

Ii-Key/HER-2/neu(776–790) hybrid peptides induce more effective immunological responses over the native peptide in lymphocyte cultures from patients with HER-2/neu+ tumors

By Sotiriadou Nectaria   Kallinteris Nikoletta   Gritzapis Angelos   Voutsas Ioannis   Papamichail Michael   Hofe Eric   Humphreys Robert   Pavlis Theodoros   Perez Sonia   Baxevanis Constantin  

Cancer Immunology, Immunotherapy, Vol. 56, Iss. 5, 2007-05 ,pp. : 601-613

Springer Publishing Company

Access to resources Recommend Favorite